| Literature DB >> 35545171 |
Elizabeth A Griffiths1, Vivek Roy2, Laura Alwan3, Kimo Bachiashvili4, John Baird5, Rita Cool6, Shira Dinner7, Mark Geyer8, John Glaspy9, Ivana Gojo10, Ashley Hicks11, Avyakta Kallam12, Wajih Zaheer Kidwai13, Dwight D Kloth14, Eric H Kraut15, Daniel Landsburg16, Gary H Lyman3, Anjlee Mahajan17, Ryan Miller18, Victoria Nachar19, Seema Patel20, Shiven Patel21, Lia E Perez22, Adam Poust23, Fauzia Riaz24, Rachel Rosovsky25, Hope S Rugo26, Shayna Simon27, Sumithira Vasu15, Martha Wadleigh28, Kelly Westbrook29, Peter Westervelt30, Ryan A Berardi31, Lenora Pluchino31.
Abstract
The NCCN Guidelines for Hematopoietic Growth Factors provide recommendations for the appropriate use of growth factors in the clinical management of febrile neutropenia (FN), chemotherapy-induced thrombocytopenia (CIT), and chemotherapy-induced anemia (CIA). Management and prevention of these sequelae are an integral part of supportive care for many patients undergoing cancer treatment. The purpose of these guidelines is to operationalize the evaluation, prevention, and treatment of FN, CIT, and CIA in adult patients with nonmyeloid malignancies and to enable the patient and clinician to assess management options for FN, CIT, and CIA in the context of an individual patient's condition. These NCCN Guidelines Insights provide a summary of the important recent updates to the NCCN Guidelines for Hematopoietic Growth Factors, with particular emphasis on the incorporation of a newly developed section on CIT.Entities:
Mesh：
Substances：
Year: 2022 PMID： 35545171 DOI： 10.6004/jnccn.2022.0026
Source DB: PubMed Journal: J Natl Compr Canc Netw ISSN： 1540-1405 Impact factor: 11.908